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SUMMARY
A previous report documented that endocrine disrupting chemicals contribute substantially to 
certain forms of disease and disability. In the present analysis, our main objective was to update a 
range of health and economic costs that can be reasonably attributed to endocrine disrupting 
chemical exposures in the European Union, leveraging new burden and disease cost estimates of 
female reproductive conditions from accompanying report. Expert panels evaluated the 
epidemiologic evidence, using adapted criteria from the WHO Grading of Recommendations 
Assessment, Development and Evaluation Working Group, and evaluated laboratory and animal 
evidence of endocrine disruption using definitions recently promulgated by the Danish 
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Environmental Protection Agency. The Delphi method was used to make decisions on the strength 
of the data. Expert panels consensus was achieved for probable (>20%) endocrine disrupting 
chemical causation for IQ loss and associated intellectual disability; autism; attention deficit 
hyperactivity disorder; endometriosis; fibroids; childhood obesity; adult obesity; adult diabetes; 
cryptorchidism; male infertility, and mortality associated with reduced testosterone. Accounting 
for probability of causation, and using the midpoint of each range for probability of causation, 
Monte Carlo simulations produced a median annual cost of €163 billion (1.28% of EU Gross 
Domestic Product) across 1000 simulations. We conclude that endocrine disrupting chemical 
exposures in the EU are likely to contribute substantially to disease and dysfunction across the life 
course with costs in the hundreds of billions of Euros per year. These estimates represent only 
those endocrine disrupting chemicals with the highest probability of causation; a broader analysis 
would have produced greater estimates of burden of disease and costs.
Keywords
disease burden; economic costs; endocrine disrupting chemicals
INTRODUCTION
In earlier reports (Bellanger et al., 2015; Hauser et al., 2015; Legler et al., 2015; Trasande et 
al., 2015) we described substantial burden of disease that is likely to be the byproduct of 
endocrine disrupting chemical (EDC) exposures in the European Union (EU). The primary 
goal of this work was to inform an impact assessment by the EU Commission, which is 
focused on the economic impact to industry of regulating EDCs in Europe. We endeavored 
to estimate the health and economic benefit of regulating EDCs in Europe, as based on 
current evidence. We identified a substantial probability of very high disease costs across the 
lifespan associated with EDC exposure in the European Union, with a median of €157 
billion cost/year across 1000 Monte Carlo simulations. This cost is approximately 1.23% of 
GDP.
In our earlier report of overall results (Trasande et al., 2015), we were only able to report on 
expert panel deliberations for obesity/diabetes; male reproductive health; and 
neurobehavioral deficits and diseases. An expert panel was also convened for female 
reproductive conditions; those deliberations are now completed, and described in an 
accompanying report (Hunt et al., 2016). The main purpose of this manuscript was therefore 
to update aggregate cost estimates to account for probability over the previously described 
exposure-outcome relationships, as well as the newly described relationships in the 
accompanying manuscript. We also present country-specific estimates of aggregate costs, as 
these have proven to be of great interest to individual member countries since the initial 
report. Finally, in a discussion, we take the opportunity to reflect on comments and other 
related reports that have also been recently published on the disease burden and costs of 
EDCs in Europe.
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METHODS
The approach to the expert panel deliberations for female reproductive conditions; 
assessment of probability of causation; selection and modeling of exposure-outcome 
relationships; and estimation of costs followed the previously published approach (Trasande 
et al., 2015). We highlight critical aspects of the analysis below for the reader who is not 
familiar with the previous work.
We followed the Institute of Medicine approach to assess the fractional contribution of the 
environment to causation of illness (1981). This approach focuses on quantifying the 
attributable fraction (AF) or increment in disease or disability above an unexposed 
proportion. The AF can be estimated insofar as there are available data about prevalence of 
exposure and relative risk (Smith et al., 1999). Having identified the attributable disease rate, 
the appropriate population or other estimates were used to calculate attributable cases, and 
cost-of-illness data were used to extrapolate attributable costs.
Leveraging a more novel approach, we adapted a weight-of-evidence characterization for 
probability of causation from the Intergovernmental Panel on Climate Change (2005). 
Evaluations of the toxicology and epidemiology literature from the Danish Environmental 
Protection Agency (Hass et al., 2012) and GRADE Working Group (Atkins et al., 2004; 
Schunemann et al., 2008) were applied to assess strength of evidence, and the strength of the 
literature was used to assess a probability that the disease costs estimated through the IOM 
approach are causally related to EDCs.
Monte Carlo modeling of total EDC-attributable costs again used 1000 simulations of 
scenarios across the fifteen exposure-outcome relationships. Recognizing that probability of 
causation could be highly influential on cost estimates, we performed three sets of these 
simulations, using midpoints of the ranges for probability of causation for each exposure-
outcome relationship as a base case scenario, and low and high bounds of the probability 
range as alternate scenarios, to assess the sensitivity of Monte Carlo simulations to this 
input. For each of the three sets of simulations, we produced ranges of burden and disease 
costs associated with EDCs. Country-specific estimates used country-specific data for the 
population affected by the relevant condition under study, and did not assume differences in 
biomarkers of exposure at the country level. Per capita costs were estimated by dividing 
aggregate costs by total population.
RESULTS
The female reproductive panel identified more modest probability (20–39%) for 
dichlorodiphenyldichloroethylene (DDE) causation in 56,700 cases of fibroids requiring 
surgical management annually, and for 145,000 phthalate-attributable cases of endometriosis 
per year. The annual estimated cost of these preventable conditions was found to be €1.41 
billion. Table 1 presents an updated list of the evaluations of fifteen exposure-outcome 
relationships across the five expert panels.
Adding these new findings to the analysis, the base case Monte Carlo simulation using the 
midpoint of each range for probability of causation produced costs between €714 million to 
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251 billion annually across the 1000 simulations (median, €163 billion; Fig. 1). This 
estimate represents a subset of the actual direct and indirect costs of diseases considered 
because of its reliance on published disease costs data. Using the 2010 EU purchasing-
power-parity corrected Gross Domestic Product (GDP) estimate of €127.9 billion (Eurostat, 
2015), the estimated costs comprise 1.28% of GDP. There is a 5% probability that costs of 
EDC exposures are less than €22.5 billion annually, a 90% probability that costs are at least 
€33.1 billion, a 75% probability that costs are at least €75.2 billion/year, a 25% probability 
of costs at least €196 billion/year, and a 10% probability of costs over €215 billion/year.
Using the lowest end of the probability range for each relationship in the Monte Carlo 
simulations produced a range of €0–238 billion (median, €112 billion) that differed 
modestly from the base case probability inputs. There is a 5% probability that costs of EDC 
exposures are less than €9.55 billion annually, a 90% probability that costs are at least €16.0 
billion, a 75% probability that costs are at least €34.1 billion/year, a 25% probability of costs 
at least €182 billion/year, and a 10% probability of costs over €204 billion/year. Applying 
the lowest end of the probability range and assuming all the relationships are independent, 
multiplying each of the probabilities for the exposure-outcome relationships suggests a very 
high (99.89% = 1–0.3 ×0.3 ×0.6 ×0.8 ×0.6 ×0.6 ×0.8 ×0.6 ×0.6 ×0.6 ×0.6 ×0.8 ×0.8 ×0.8 
×0.8) probability that EDCs contribute to disease in Europe. Leaving aside the highly 
probable costs of developmental neurotoxicity from organophosphate pesticide and 
brominated flame retardants, there is still a substantial probability (>98.8%) that one or more 
of the other exposure-outcome relationships are causal. Using the highest end of the 
probability ranges narrowed the range of costs more substantially (€20.0–256 billion; 
median €180 billion). There was a 21.3% probability of costs under €100 billion, and a 
33.0% probability of costs over €200 billion.
We present base case scenario estimates of country-specific costs in Table 2. The largest 
burden after accounting for probability of causation was borne by France (€25.6 billion), 
Germany (€24.6 billion), the United Kingdom (€24.7 billion), and Italy (€17.5 billion). As a 
percentage of country GDP, Slovakia’s cost (3.21%) was highest, followed by Ireland 
(1.75%) and Bulgaria (1.56%). Per capita costs were €322 across the entire European Union, 
and highest in Luxembourg (€791), Ireland (€583), and the Netherlands (€411).
DISCUSSION
The findings of the accompanying manuscript (Hunt et al., 2016) reinforces our earlier 
findings – indeed, there is a substantial probability of very high disease costs across the 
lifespan associated with EDC exposure in the European Union. For some perspective, the 
median €163 billion cost/year we identified is approximately one-fifth the €798 billion 
European cost of brain disorders in 2010 (Gustavsson et al., 2011), or 1.28% of GDP. 
Dividing the total cost by the European population of 506 million, suggests a per capita cost 
of €322, or €1288 for a family of four.
As the accompanying manuscript emphasizes (Hunt et al., 2016), the additional costs we 
have included in these updated estimates are a subset of the actual costs of conditions that 
affect women and can be etiologically attributed to EDCs. There is substantial evidence, 
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recently summarized by the Endocrine Society, for effects of a host of EDCs, including 
bisphenol A (BPA), phthalates, pesticides, and persistent organic pollutants (POPs) on the 
developing ovary and reproductive tract.
We wish to reflect in the remainder of this manuscript on comments and other related reports 
that have also been recently published on the disease burden and costs of EDCs in Europe. 
Woodruff has rightly identified that our estimate of costs because of phthalate-attributable 
mortality owing to reductions in testosterone may be highly underestimated (Woodruff, 
2015). If the value of a statistical life is $4–9 million, as described by multiple authors 
(Viscusi & Aldy, 2003), then the costs of the early mortality we identified would be $99.3–
223 billion rather than $7.96 billion. We took a human capital approach to our estimation, 
rather than a willingness-to-pay approach, and so revision of the $7.96 billion estimate to the 
higher number is not appropriate at this time. However, it is fair to state that lost economic 
productivity represents a subset of the welfare losses associated with early mortality. We 
agree that the total costs of phthalate-attributable mortality because of reductions in 
testosterone are likely to be much higher. Thus, it is an important discussion to determine 
whether the $4–9 million value of a statistical life is appropriate here, but we note that this is 
another source of potential underestimation of the cost of human exposures.
We also note a difference in the estimation of attributable infertility costs performed by the 
Nordic Council of Ministers (Olsson, 2014). We modeled increases in infertility in a cohort 
of 20–40 year old women estimating annual costs because of phthalate exposures, which 
implicitly assumes that all women in that cohort who are not using contraception are indeed 
trying to conceive, with a subset of those seeking medical care and actually resulting in 
health care expenditures. In comparison, the Nordic Council modeled an attributable fraction 
of measurable assisted reproductive technology treatments, assuming that a percentage was 
because of a group of endocrine disrupting chemicals. We identified 618,000 additional 
assisted reproductive technology procedures, whereas the Nordic Council identified 26,600. 
The Nordic Council included indirect and intangible costs, which represent more than two-
thirds of its €263 million cost estimate of these cases, whereas our €4.71 billion estimate 
includes only direct costs.
Rather than revising our estimate at this time, which differs from the Nordic estimate 
because of different assumptions made explicit in both publications, we note that assisted 
reproductive technology procedures are most frequent among older women within the 20–40 
year old range. If indeed the more appropriate population is 30–40 year old women instead, 
our estimate of attributable cases would be 50% lower, although we note that our estimate of 
costs per case may have been conservative by a factor of three. We also note that we 
assumed a single infertility treatment cycle per case of phthalate-induced infertility, whereas 
more than one treatment cycle may be needed, whether for a single pregnancy or a 
subsequent one in a persistently subfertile couple. It is best at this point to lay these 
assumptions open for discussion, noting that the two economic estimates may span a range 
that represents actual costs.
This latter set of concerns does not diminish the overall austerity of the approach we took in 
this exercise. Our work surely represents a substantial underestimate of actual EDC-
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attributable disease given its focus on <5% of EDCs; examination of a subset of health 
effects; and exclusion of human suffering and other societal costs of EDC-attributable 
diseases. In addition, recent work has suggested that the biomarker-based studies may suffer 
from exposure imprecision that underestimates the degree of the actual exposure-response 
relationships used in modeling disease burden (Budtz-Jørgensen et al., 2003). Future work 
can interrogate a broader array of EDCs, and effects of mixtures, using systematic review 
methods which others have developed (Rooney et al., 2014; Thayer et al., 2014).
We do still acknowledge some limitations in our approach, particularly with respect to 
modeling country-level costs. We were unable to model differences in exposure at the 
country level because of lack of exposure data, and could only account for purchasing power 
differences in modeling country-level costs. More refined, country-level data about EDC 
exposures are clearly needed, and can inform the effect of policy interventions as well as 
identification of subgroups and areas of greatest concern.
CONCLUSIONS
Assessing EDC-associated costs is not easy, but we have quantified these costs in Europe in 
a straightforward and transparent methodology grounded on work first conducted by the 
Intergovernmental Panel on Climate Change and the World Health Organization. This work 
was assessed by a group of internationally recognized experts in epidemiology, toxicology, 
economics, EDCs, and neurodevelopment. Concerns about uncertainties do not diminish the 
impact of our conservatively formulated findings for policy makers considering methods to 
reduce exposure to the EDCs of greatest concern. The economic rewards of doing so are 
likely to be in the billions of Euros and accrue annually insofar as alternatives free of health 
effects are used.
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Figure 1. 
Economic costs of EDC exposures in EU, Monte Carlo Analysis. The numbers on the X-
axis denote cumulative probability across the 1000 simulations for base case probability of 
causation, as well as low and high bounds for probability of causation.
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